Cognitive Longevity Support.

DHA is the dominant long-chain polyunsaturated fatty acid in grey-matter phospholipids, and membrane phosphatidylethanolamine and phosphatidylcholine pools cannot be built to their normal composition without it. Blends aimed at cognitive ageing lean on that structural role rather than on any single acute effect. The relationship is compositional biochemistry, not a measured clinical outcome for the blend itself.

EPA and DHA together supply the substrate for membrane remodelling and for resolvin and protectin synthesis. Reviews of nutritional strategies for healthy ageing repeatedly place long-chain omega-3 intake among the interventions with the most human data behind them. What that literature reports are population associations and biomarker shifts, so read the pairing as mechanistic support rather than an effect size for a specific blend.

Choline is the substrate that choline acetyltransferase uses to make acetylcholine, and it also feeds phosphatidylcholine synthesis and, through betaine, one-carbon metabolism. Cognitive-ageing blends commonly include a choline donor for that reason. Adequacy of intake is the claim here, not an effect on any measured cognitive score.

Methionine synthase needs methylcobalamin to remethylate homocysteine, and without it the folate cycle stalls in a methyl-trapped state. Homocysteine is a biochemical marker, not a cognitive outcome. B12 belongs in longevity-oriented formulas because absorption falls with age, which is a nutritional argument rather than a clinical one.

5-methyltetrahydrofolate donates the methyl group that methionine synthase transfers to homocysteine, regenerating methionine and then SAM-e for methylation reactions throughout the brain. Folate and B12 fail together, so pairing them is standard formulation practice. The pairing supports a normal methylation cycle; it is not an effect on memory.

Pyridoxal-5-phosphate is the cofactor for cystathionine beta-synthase, the enzyme that routes homocysteine away from remethylation and toward cysteine. B6, B12 and folate cover the three exits of that node, which is why they appear as a set. Again a marker pathway, not a measured cognitive endpoint.

A 2025 systematic review and meta-analysis pooled curcumin supplementation trials in the context of cognitive ageing and is the most directly relevant pooled evidence in this candidate set. Curcumin acts on redox and inflammatory signalling rather than on any single neurotransmitter. Pooled estimates carry the heterogeneity of the trials that went into them, which the review itself discusses.

Piperine slows the glucuronidation that clears curcuminoids from the gut wall and liver, which raises measured plasma curcumin. Any blend that carries curcumin for a cognitive-ageing purpose faces the same bioavailability ceiling. The pairing changes exposure, not the underlying activity of the molecule.

Spermidine is a polyamine linked to autophagic turnover in neurons, and a 2026 review gathers the animal and human work on it in the ageing brain. Most of the mechanistic weight sits in animal models. Read it as a mechanistic rationale for inclusion in a longevity blend, not as a human outcome.

NR enters the NAD salvage pathway through nicotinamide riboside kinase, raising cellular NAD+ available to sirtuins and to mitochondrial dehydrogenases. Longevity-oriented formulas use it for that biochemical position. Raised NAD+ is a measurable biochemical change and not itself a cognitive result.

Resveratrol and NAD precursors converge on sirtuin-dependent signalling from opposite ends, one as an activator and one as substrate supply. Systems-biology work on Mediterranean dietary patterns maps polyphenols onto several of the same longevity networks. Those are network models built from observational and mechanistic data, so the confidence stays mid-range.

Pterostilbene is the dimethylated analogue of resveratrol and is more lipophilic, which changes its distribution and its resistance to first-pass conjugation. Formulas pair the two to cover different exposure profiles from one polyphenol class. The comparison is pharmacokinetic; neither is a substitute for evidence of an effect.

Phosphatidylserine is an inner-leaflet phospholipid that supports normal membrane curvature and the docking of several signalling kinases. It sits alongside phosphatidylcholine in the same membrane pool that citicoline and DHA feed. Inclusion is a compositional argument about membrane substrate supply.

Bacosides are the standardised markers in bacopa extracts and the herb is one of the more frequently trialled botanicals in memory-oriented formulas. It is included for a different mode of action than the nutrient cofactors, which is why blends carry both. The human trial base is modest in size and duration.

Ginkgolides antagonise platelet-activating factor, which is a real pharmacological effect and the reason ginkgo carries a bleeding-risk flag when stacked with fish oil or other antiplatelet agents. In a cognitive blend it is included for cerebral perfusion rationale. The interaction direction worth flagging is the additive platelet effect, not a benefit.

L-theanine is a glutamate analogue that crosses the blood-brain barrier and shifts cortical alpha activity, and it blunts the jittery edge of caffeine without removing the alertness. Longevity-oriented cognitive blends use it as the calming counterweight to any stimulant they carry. Effects reported are acute and state-related rather than durable.

Caffeine blocks adenosine A1 and A2A receptors, producing an acute alertness effect that is easy to mistake for a durable cognitive change. Reviews of nutrition in cognitively demanding performance settings put caffeine among the few interventions with consistent acute data. Acute alertness and long-horizon cognitive ageing are different endpoints and blends should not blur them.

Creatine buffers ATP through the creatine kinase reaction in neurons as well as muscle, and brain phosphocreatine can be measured directly by phosphorus spectroscopy. That makes it a bioenergetic rather than a neurotransmitter play. Brain creatine loading is slower and less complete than muscle loading.

Ubiquinone shuttles electrons from complexes I and II to complex III and is regenerated as ubiquinol, which also acts as a lipid-phase antioxidant. Endogenous synthesis declines with age, which is the stated rationale for including it in longevity formulas. The cofactor role is settled; the clinical translation in cognition is not established.

Lipoic acid is the covalently bound cofactor of pyruvate and alpha-ketoglutarate dehydrogenase, and the free form regenerates oxidised vitamin C and glutathione. Both halves of that description are textbook. It is one of the few antioxidants that works in aqueous and lipid phases alike.

Acetyl-L-carnitine donates acetyl groups that can feed acetyl-CoA pools and, through them, acetylcholine synthesis, while carnitine itself moves long-chain fatty acids into mitochondria. The acetylated form crosses the blood-brain barrier more readily than plain carnitine. The biochemistry is settled; the size of any cognitive effect is a separate question.

Lutein accumulates in retinal and cortical tissue and is among the carotenoids measured as a biomarker in healthy-longevity work. Its concentration in brain tissue tracks dietary intake. Biomarker status is what the literature supports, and a biomarker is not an outcome.

Zeaxanthin sits alongside lutein in the same xanthophyll pool and the two are absorbed through the same micellar route, so they compete when one is given in gross excess. Formulas usually keep them at a fixed ratio for that reason. The pairing is formulation convention grounded in absorption biochemistry.

Astaxanthin spans the lipid bilayer with polar groups at both ends, which lets it quench radicals at the membrane surface and inside it. That geometry is why it behaves differently from beta-carotene. Human data in cognitive ageing are thin and mostly biomarker-based.

Vitamin D receptors are expressed in neural tissue and circulating 25-hydroxyvitamin D falls with age and reduced sun exposure. Multi-domain intervention programmes in older adults commonly include it as part of a nutritional arm. Trials of that kind test packages, so no single component can be credited with the result.

Magnesium is required by every ATP-dependent enzyme, since the true substrate is the Mg-ATP complex, and it also sits in the NMDA receptor channel as a voltage-dependent block. Both roles are textbook. Cognitive blends include it for the cofactor role rather than any direct memory claim.

Zinc is structural in hundreds of enzymes and transcription factors and is concentrated in hippocampal mossy-fibre vesicles. Long-term high-dose zinc lowers copper absorption through metallothionein induction, so a longevity formula that carries zinc should account for copper. That competition is established pharmacology.

Zinc induces intestinal metallothionein, which binds copper preferentially and sheds it with the enterocyte, so sustained zinc intake lowers copper status. Copper is itself a cofactor for cytochrome c oxidase and superoxide dismutase 1 in neural tissue. This is the classic reason to state the zinc-to-copper ratio in a long-term formula.

Urolithin A is produced by gut bacteria from dietary ellagitannins and only a minority of people convert efficiently, which is why it is supplied directly. Its studied mechanism is mitophagy signalling. Most of the mechanistic work is preclinical and the human data centre on muscle rather than cognition.

Gut microbial communities produce short-chain fatty acids and neuroactive metabolites that reach the circulation, and a placebo-controlled prebiotic study in children reported changes in emotional behaviour indicators. That population is not older adults and the endpoints were behavioural indicators, not cognition. It supports the axis existing, not a longevity claim.

Rosavins and salidroside are the standardised markers, and rhodiola is used in blends for perceived-fatigue endpoints under load rather than for memory. Its inclusion changes what the formula is aimed at. Human trials are short and use self-reported scales.

Huperzine A is a reversible acetylcholinesterase inhibitor, which is a genuine pharmacological action rather than a nutritional one. Stacking it with a choline donor raises acetylcholine from both the supply and the breakdown side. Because it is pharmacologically active it warrants care in any long-horizon formula and should not be treated as a nutrient.